1. EconStor

Browsing All of EconStor by Author Stargardt, Tom


Showing results 1 to 20 of 21
 next >
Year of PublicationTitleAuthor(s)
2004Bürgerversicherung: Die Wirkung von Kopfprämien auf den ArbeitsmarktFarhauer, Oliver; Borchardt, Katja; Stargardt, Tom
2005Defining benefit catalogues and entitlements to health care in Germany: Decision makers, decision criteria and taxonomy of cataloguesBusse, Reinhard; Stargardt, Tom; Schreyögg, Jonas; Simon, Claudia; Martin, Maria
2011Effect of type of insurance and income on waiting time for outpatient careRoll, Kathrin; Stargardt, Tom; Schreyögg, Jonas
2012Measuring the relationship between costs and outcomes: The example of Acute Myocardial Infarction in German hospitalsStargardt, Tom; Schreyögg, Jonas; Kondofersky, Ivan
2020The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in GermanyBlankart, Katharina Elisabeth; Stargardt, Tom
2020Cost–Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model SimulationBaumann, Mathias; Stargardt, Tom; Frey, Simon
2020Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UKVadia, Rucha; Stargardt, Tom
2020Do discontinuities in marginal reimbursement affect inpatient psychiatric care in Germany?Pott, Clara; Stargardt, Tom; Schneider, Udo; Frey, Simon
2022Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes PatientsBöhm, Anna-Katharina; Schneider, Udo; Stargardt, Tom
2022An econometric approach to aggregating multiple cardiovascular outcomes in German hospitalsMeggiolaro, Angela; Blankart, Carl Rudolf; Stargardt, Tom; Schreyögg, Jonas
2022Does health technology assessment compromise access to pharmaceuticals?Büssgen, Melanie; Stargardt, Tom
2023Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”Büssgen, Melanie; Stargardt, Tom
202310 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?Büssgen, Melanie; Stargardt, Tom
2023Braving the waves: exploring capability well-being patterns in seven European countries during the COVID-19 pandemicHimmler, Sebastian; van Exel, Job; Brouwer, Werner; Neumann-Böhme, Sebastian; Sabat, Iryna; Schreyögg, Jonas; Stargardt, Tom; Barros, Pedro Pita; Torbica, Aleksandra
2023Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel diseaseSteiner, Isa Maria; Bokemeyer, Bernd; Stargardt, Tom
2023Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”Büssgen, Melanie; Stargardt, Tom
2023Does health technology assessment compromise access to pharmaceuticals?Büssgen, Melanie; Stargardt, Tom
2023Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel diseaseSteiner, Isa Maria; Bokemeyer, Bernd; Stargardt, Tom
2024The European COvid Survey (ECOS): Technical reportSabat, Iryna; Neumann-Böhme, Sebastian; Stargardt, Tom; Schreyögg, Jonas
2025Does timing matter? The role of health information shocks in measuring willingness to payBrinkmann, Carolin; Neumann-Böhme, Sebastian; Brouwer, Werner B. F.; Stargardt, Tom
Showing results 1 to 20 of 21
 next >